Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.074 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.1254 | 1 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.074 | 0.2852 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1233 | 0.9706 | 0.9706 |
Onchocerca volvulus | 0.1254 | 1 | 0.5 | |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.074 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1254 | 1 | 1 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.1254 | 1 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.074 | 0.2852 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.074 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1233 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.1233 | 0.9706 | 0.9604 |
Loa Loa (eye worm) | hypothetical protein | 0.1254 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.1233 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1233 | 0.9706 | 0.9706 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 18 % | Cytotoxicity against human KB cells assessed as growth inhibition at 10 '-6 M after 72 hrs by MTS assay | ChEMBL. | 22257529 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.